PURPOSE: To evaluate the effect of @entity1259 on therapeutic response and survival in @entity1 with @entity1892 ( @entity1892 ) treated with pulsed high-dose @entity5805 . @entity1 AND METHODS: A total of 170 untreated @entity1 with advanced/active @entity1892 were randomly assigned to receive either eight cycles of high-dose @entity5805 (15 mg/m2/d) plus @entity229 (100 mg/d) for 5 days ( @entity2033 ; arm A) or eight cycles of @entity2033 plus @entity1259 60 mg/m2 intravenous on day 1 (arm B). The responding @entity1 were randomly assigned to either maintenance therapy with interferon alfa ( @entity3027 -2a; 3 MU, three times weekly) for 12 months or observation. RESULTS: There were 160 assessable @entity1 (82 males, 78 females; median age, 63 years; range, 33 to 77 years); 77 @entity1 were assigned to arm A, and 83 were assigned to arm B. Induction therapy led to 47 complete responses (CRs; 29.4%) and 68 partial responses (PRs; 42.5%), with no significant difference between the two arms (60 CR + PR in arm A [77.9%] and 55 CR + PR in arm B [66.3%]; P =.07). After a median follow-up of 38 months (range, 2 to 103 months), there was no between-group difference in @entity1349 ( @entity1349 ; P =.45), failure-free survival (P =.07), or progression-free survival (PFS; P =.5). Eighty-eight @entity1 were randomly assigned to either @entity3027 -2a (n = 43) or observation (n = 45), without any difference in 3-year PFS (44% and 42%, respectively). Univariate analysis showed that @entity1349 was influenced by age, @entity417 , serum @entity880 dehydrogenase levels, and International Prognostic Index distribution; multivariate analysis identified age and @entity417 as having influence on @entity1349 . CONCLUSION: @entity2033 treatment outcome in @entity1892 @entity1 was good (50% 3-year PFS, minimal @entity137 , and low costs); @entity1259 did not add any advantage. One-year @entity3027 maintenance treatment did not prolong response duration.

Treatment of XXXX : final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD-CHL-P'] @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['INFL', 'indolent nonfollicular B-cell lymphomas'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity3027 :: ('3439', 'Gene') :: ['IFNalpha'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1892 :: (MESH:D016393,Disease) :: ['indolent B-Cell nonfollicular lymphomas']
